- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01541345
Lateral Ridge Augmentation Using Autogenous Bone Blocks or Xenogenic Bone Block Grafts Loaded With Recombinant Human Bone Morphogenic Protein 2
A Phase III, Randomized, Controlled Clinical Trial of Lateral Ridge Augmentation Using Autogenous Bone Blocks or Xenogenic Bone Block Grafts Loaded With Recombinant Human Bone Morphogenic Protein 2
Since there are no clinical studies available comparing the gold standard (autogenous bone graft plus resorbable membrane) to the promising combination of xenogenic bone graft loaded with rhBMP-2 in combination with a collagen membrane for localized ridge augmentation, the present exploratory study has been designed.
The aim of the present study is therefore to test whether or not the application of a xenogenic bone block loaded with rhBMP-2 will results in clinically, radiographically and histologically similar outcomes as the gold standard (autogenous bone block) for the regeneration of chronic ridge defects.
The investigators expect that there is no difference in bone quantity and quality between the two methods and that the use of the test treatment will be more user and patient friendly according to the patient perception/acceptance since no second surgical site will be necessary as well as cause less complications.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Graz, Austria
- Department of Oral Surgery & Radiology, Dental School, Medical University of Graz
-
-
-
-
-
Zurich, Switzerland, 8032
- Center of Dental Medicine Clinic of Reconstructive Dentistry
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- requiring implant therapy for the reconstruction of 1 to 4 missing teeth
- revealing insufficient bone volume for implant placement (cases where less than 50% of the implant surface would be surrounded by native bone) requiring bone augmentation procedure
Exclusion Criteria:
- Medication with a contraindication for implant therapy
- Previous administration of InductOs
- Skeletal immaturity
- Any active malignancy or patient undergoing treatment for a malignancy
- An active infection at the operative site
- Persistent compartment syndrome or neurovascular residua of compartment syndrome
- Pathological fractures such as those observed in (but not limited to) Paget's disease or in metastatic bone
- Contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to class of drugs or the investigational product,
- Contraindications on ethical grounds,
- Pregnancy,
- Intention to become pregnant during the course of the study,
- Breast feeding,
- Treatment with other investigational products,
- Other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc),
- Known or suspected non-compliance, drug or alcohol abuse,
- Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia or confusional state of the subject,
- Participation in another study with investigational drug within the 30 days preceding and during the present study,
- Previous enrolment into the current study,
- Enrolment of the investigator, his/her family members, employees and other dependent persons,
- Patients where autogenous bone cannot be harvested.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Control Group (A)
Bone augmentation will be performed using autogenous bone from the retromolar or chin area followed by a fixation with titanium screws at the recipients site; filled with deproteinized bovine bone mineral (DBBM) particles (Bio-Oss®, Geistlich Pharma AG, Wolhusen, Switzerland) and covered with a collagen membrane (Bio-Gide®, Geistlich Pharma AG, Switzerland).
These course of action is well documented in the literature and standard procedures.
|
Bone augmentation will be performed using autogenous bone from the retromolar or chin area followed by a fixation with titanium screws at the recipients site; filled with deproteinized bovine bone mineral (DBBM) particles (Bio-Oss®, Geistlich Pharma AG, Wolhusen, Switzerland) and covered with a collagen membrane (Bio-Gide®, Geistlich Pharma AG, Switzerland)
|
Experimental: Test group (B)
The bone augmentation will be performed using a deproteinized bovine bone mineral (DBBM) block (Bio-Oss Spongiosa Block®, Geistlich Parma AG, Wolhusen, Switzerland) and a collagen membrane (Bio-Gide®, Geistlich Pharma AG, Switzerland) similarly to the control group.
In addition, DBBM will be loaded with rhBMPH-2 (InductOs®, Pfizer AG, Zurich, Switzerland).
|
CE-marked medical device Bio-Oss Spongiosa Block® (xenogenic bone) loaded with InductOs® (1.5 mg Dibotermin alfa / ml) covered with Bio-Gide® (collagen membrane).
One time application at augmentation surgery.
CE-marked medical device Bio-Oss Spongiosa Block® (xenogenic bone) loaded with InductOs® (1.5 mg Dibotermin alfa / ml) covered with Bio-Gide® (collagen membrane)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bone quality/quantity
Time Frame: 4 month after augmentation surgery
|
Bone quantity at 4 months after augmentation surgery, measured manually by ridge measurements and volumetrically on the basis of optical impressions and radiological assessment (X-ray and cone beam CT).
Bone quality at 4 months after augmentation surgery, measured by histological assessment (yields different proportion per patient).
|
4 month after augmentation surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complications
Time Frame: 8 days and 4 month after augmentation surgery
|
Complications (soft tissue, sensitivity) measured at suture removal (8 days after augmentation surgery) and 4 months after augmentation surgery.
Any adverse events will be recorded for the treatment period from visit 1 to 4.
|
8 days and 4 month after augmentation surgery
|
Bone quantity
Time Frame: at screening, augmentation surgery, suture removal, and during follow-up
|
Bone quantity measured at screening, augmentation surgery, suture removal, and during follow-up
|
at screening, augmentation surgery, suture removal, and during follow-up
|
Patient's perception/acceptance
Time Frame: 8 days after augmentation surgery
|
Patient's perception/acceptance (visual analogue scale VAS) measured at suture removal (8 days after augmentation surgery)
|
8 days after augmentation surgery
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Daniel S Thoma, Prof. Dr., Clinic of Reconstructive Dentistry
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2012DR2009
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Missing Teeth
-
Air Force Military Medical University, ChinaNational Natural Science Foundation of ChinaUnknown
-
University GhentCompletedMissing Several Teeth | Minimum of 2 Dental Implants NeededBelgium
-
Cairo UniversityUnknownMissing Maxillary Anterior TeethEgypt
-
Misr University for Science and TechnologyCompleted
-
Diana Mostafa HabebRecruitingTooth Discoloration | Destructed Teeth Restored by Zirconia Crowns | Zirconia Crowns | Decayed, Missing, and Filled TeethEgypt
-
Damascus UniversityCompletedCrowding | Malocclusion, Angle Class I | Malocclusion; Displaced or Missing TeethSyrian Arab Republic
-
Hong Kong Brånemark Osseointegration CenterDentsply Sirona Implants and ConsumablesUnknownMalocclusion; Displaced or Missing TeethChina
-
University Hospital, MontpellierCompletedTooth Decay | Missing Tooth/TeethFrance
-
Medical University of GrazRecruitingMissing ToothAustria
-
Cairo UniversityRecruitingEffect of Piezo-surgical Implant With Laser on Pain and Swelling in Patients With Missing TeethEgypt
Clinical Trials on Autogenous bone graft
-
Kafrelsheikh UniversityCompletedPeri-Implantitis | Alveolar Bone Loss | Dental Implant Failure NosEgypt
-
Cairo UniversityRecruitingIntrabony Periodontal DefectEgypt
-
Kafrelsheikh UniversityCompleted
-
Spine WaveTerminatedDegenerative Disc Disease | Spondylolisthesis | StenosisUnited States
-
Ain Shams UniversityActive, not recruitingImmediate Implant PlacementEgypt
-
Ferring PharmaceuticalsCompletedArthrodesis Surgery Involving the Hindfoot or AnkleUnited States, Canada
-
Medtronic Spinal and BiologicsAverion International Corporation; Baim Institute for Clinical ResearchWithdrawnAlveolar Bone Loss in Mandible | Edentulous Alveolar Ridge In Mandible
-
Cairo UniversityNot yet recruiting
-
Medtronic Spinal and BiologicsTerminated
-
Cairo UniversityUnknown